Ironwood Pharmaceuticals (IRWD) Fundamental Analysis: Revenue, Earnings & Valuation

7.06 / 10

Outperform

Fundamental analysis rates IRWD as Outperform with a 7.1/10 quality score. Strong inventory turnover and cash‑to‑market boost its profile, while negative revenue growth and a low PB‑ROE raise concerns. Overall fundamentals are favorable but not without risk.

Analysis Checks(9/10)

Revenue-MV

Value-0.58

Score3/3

Weight17.02%

1M Return9.01%

Total operating revenue (YoY growth rate %)

Value-15.72

Score2/3

Weight-1.30%

1M Return-1.06%

Inventory turnover ratio

Value103.94

Score3/3

Weight10.79%

1M Return6.74%

Gross profit margin (%)

Value100.00

Score2/3

Weight2.46%

1M Return1.69%

PB-ROE

Value0.31

Score1/3

Weight9.04%

1M Return5.29%

Income tax / Total profit (%)

Value65.70

Score2/3

Weight1.44%

1M Return1.04%

Fixed assets turnover ratio

Value20.95

Score2/3

Weight-0.72%

1M Return-0.51%

Cost of sales ratio (%)

Value64.41

Score3/3

Weight6.24%

1M Return4.32%

Asset-MV

Value-0.55

Score3/3

Weight22.90%

1M Return11.84%

Cash-MV

Value1.32

Score3/3

Weight32.13%

1M Return13.34%

Is IRWD undervalued or overvalued?

IRWD scores 7.06/10 on fundamentals and holds a Discounted valuation at present. Backed by its 0.00% ROE, 8.11% net margin, 21.93 P/E ratio, -2.01 P/B ratio, and 1400.00% earnings growth, these metrics solidify its Outperform investment rating.